Heart failure
Conditions
Interventions
perindopril group:perindopril
Sponsors
The First Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients treated with Sacubitril/Valsartan / perindopril tablets; 2. Male or non-pregnant or non-lactating female patients = 18 years of age. 3. Patients with spontaneous new left ventricular acute myocardial infarction; 4. LVEF =45% after AMI presentation; 5. Hemodynamically stable defined as: SBP = 95mmHg ( patients who received ACEi/ARB before) SBP = 100 mmHg ( patients who did not receive ACEi/ARB before) 6. The subjects volunteered to join the study and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. History of hypersensitivity to the study drugs or drugs of similar chemical classes or known intolerance or contraindications to study drugs or drugs of similar chemical classes including ACE inhibitors, ARB or NEP inhibitors; 2. Patients with a known history of angioedema; 3. Known history of chronic HF prior to Screening; 4. Cardiogenic shock within the last 24 hours prior to Screening; 5. Persistent clinical HF at the time of Screening; 6. Coronary artery bypass graft (CABG) performed or planned; 7. Combined with right ventricular MI; 8. Symptomatic hypotension at screening; 9. Stroke or transient ischemic attack within one month prior to Screening; 10. Known or suspected bilateral renal artery stenosis; 11. Clinically significant obstructive cardiomyopathy; 12. Open-heart surgery performed within one month prior to Screening; or planned cardiac surgery w/in the 3 months prior to Screening; 13. eGFR 5.2 mmol /L; 15. Known hepatic impairment (as evidenced by total bilirubin > 3.0 mg/dL or increased ammonia levels, if performed), or history of cirrhosis with evidence of portal hypertension such as esophageal varices; 16. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin) within the past 3 years with a life expectancy of less than 1 year. 17. Those who were participating in another clinical trial had not yet reached the end of the study or were planning to participate in another clinical trial within six months of taking the drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LVEF;Left ventricular volume;Left ventricular diameter;Left ventricular fibrosis; | — |
Countries
China
Contacts
Public ContactZhang Bo
The First Affiliated Hospital of Dalian Medical University
Outcome results
None listed